Literature DB >> 17630459

The impact of an AIDS vaccine in developing countries: a new model and initial results.

John Stover1, Lori Bollinger, Robert Hecht, Clara Williams, Eva Roca.   

Abstract

A new model was developed to examine the potential impacts of an AIDS vaccine in developing countries. The findings suggest that even a modestly efficacious first-generation vaccine could have a profound effect on the AIDS pandemic. A vaccine with 50 percent efficacy provided to 30 percent of the population would reduce new annual infections by 34 percent (seventeen million infections avoided) over fifteen years and result in substantial financial savings. A more efficacious vaccine, combined with expanded delivery, would do even more to control the pandemic. It therefore makes sense to continue investing in AIDS vaccine research and development and the eventual manufacture and widespread distribution of a vaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630459     DOI: 10.1377/hlthaff.26.4.1147

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  23 in total

1.  Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

Authors:  A M Young; R J DiClemente; D S Halgin; C E Sterk; J R Havens
Journal:  AIDS Behav       Date:  2014-09

2.  Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

Authors:  Susan Zolla-Pazner; X-P Kong; Xunqing Jiang; Timothy Cardozo; Arthur Nádas; Sandra Cohen; Maxim Totrov; Michael S Seaman; Shixia Wang; Shan Lu
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

3.  Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.

Authors:  Elisa F Long; Margaret L Brandeau; Douglas K Owens
Journal:  Vaccine       Date:  2009-07-08       Impact factor: 3.641

4.  Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES).

Authors:  Peter A Newman; Sung-Jae Lee; Naihua Duan; Ellen Rudy; Terry K Nakazono; John Boscardin; Lisa Kakinami; Steven Shoptaw; Allison Diamant; William E Cunningham
Journal:  Health Serv Res       Date:  2009-09-24       Impact factor: 3.402

5.  Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.

Authors:  Igor M Belyakov; Jeffrey D Ahlers; Gary J Nabel; Bernard Moss; Jay A Berzofsky
Journal:  Virology       Date:  2008-09-14       Impact factor: 3.616

Review 6.  Lessons learned from HIV vaccine clinical efficacy trials.

Authors:  Tracey A Day; James G Kublin
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

7.  The Price of Prevention: Cost Effectiveness of Biomedical HIV Prevention Strategies in South Africa.

Authors:  Nishila Moodley; Glenda Gray; Melanie Bertram
Journal:  Clin Res HIV AIDS       Date:  2016-11-27

8.  Assessing the population health impact of market interventions to improve access to antiretroviral treatment.

Authors:  Till Bärnighausen; Margaret Kyle; Joshua A Salomon; Brenda Waning
Journal:  Health Policy Plan       Date:  2011-09-13       Impact factor: 3.547

Review 9.  HIV prevention cost-effectiveness: a systematic review.

Authors:  Omar Galárraga; M Arantxa Colchero; Richard G Wamai; Stefano M Bertozzi
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

10.  Notions of synergy for combinations of interventions against infectious diseases in heterogeneously mixing populations.

Authors:  Peter J Dodd; Peter J White; Geoff P Garnett
Journal:  Math Biosci       Date:  2010-07-01       Impact factor: 2.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.